

January 18, 2024

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Pursuant to Regulation 30, read with Clause 20 Para A of Part A of Schedule III, of SEBI Listing Regulations, we would like to inform that one of the Subsidiary Company has received a suspension order of drug license for its stores situated at locations as mentioned below:

Name(s) of the Authority:	Nature and details of the action(s) taken, initiated or order(s) passed.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Details of the violation(s)/contravention(s) committed or alleged to be committed
Assistant Director & Drug sales licensing authority, Drug control administration, Vizianagaram District, Andhra Pradesh	Suspension of Drug License for 7days	Order received on January 17, 2024.	Violation of various conditions of license issued pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945
Assistant Director, Drugs Control Administration, Bangalore Circle-01 , Karnataka	Suspension of drug license for 1 days	Order received on January 17, 2024.	

There is no major financial impact. The Company is taking corrective action in this regard.

Kindly take the same on records.

For MedPlus Health Services Limited



Manoj Kumar Srivastava
Company Secretary & Compliance Officer
FCS 7460

 040-6724 672